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Imbalances between excitation and inhibition in synaptic transmission and neural circuits have been implicated in
autism spectrum disorders. Excitation and inhibition imbalances are frequently observed in animal models of autism
spectrum disorders, and their correction normalizes key autistic-like phenotypes in these animals. These results
suggest that excitation and inhibition imbalances may contribute to the development and maintenance of autism
spectrum disorders and represent an important therapeutic target.
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SynapseISShttp://dx.doi.org/10.1016/j.biopsych.2016.05.011A tight balance between excitation and inhibition (E/I balance)
in synaptic inputs to a neuron and in neural circuits is
important for normal brain development and function. Accord-
ingly, disturbed E/I balances have been implicated in various
brain disorders, including autism spectrum disorders (ASDs)
(1–6). An early, illuminating review by Rubenstein and Merze-
nich (1) suggested the hypothesis that an increased E/I ratio in
sensory, mnemonic, social, and emotional systems can cause
ASDs. Since that time, a large body of clinical and neuro-
biological data has accumulated to support and reﬁne this
hypothesis.
ASDs represent neurodevelopmental disorders character-
ized by social deﬁcits and repetitive behaviors and accom-
panying comorbidities, including intellectual disability,
epilepsy, hyperactivity, and anxiety. ASDs are associated with
heterogeneous genetic variations, and the number of ASD-
associated genes has risen to approximately 800 (7). ASDs are
now the subject of intense worldwide investigations that seek
to identify key underlying mechanisms capable of accounting
for a large portion of ASD-related genetic variations and thus
can serve as important therapeutic targets.
This review summarizes results from animal models of
ASD showing altered E/I balances. E/I balance is established
and tightly regulated by a large number of factors, making it
difﬁcult to differentiate primary changes from secondary
alterations in model animals, as was recently noted (3).
Therefore, the emphasis is on those models that demon-
strate rescue of ASD phenotypes using pharmacologic or
cell type–speciﬁc gene-rescue approaches, or those models
that use conditional gene-ablation approaches. Though
valuable, other studies, including some that do not strongly
support a causal relationship between the observed E/I
imbalances and autistic-like phenotypes, are unavoidably
less highlighted.& 2016 Society o
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SEE COMMENTAE/I IMBALANCE AND AUTISTIC-LIKE BEHAVIORS
Abnormal connectivity and neural integration (or temporal bind-
ing), manifesting as abnormal brain rhythms, have been sug-
gested to underlie ASDs (8). Recent optogenetic studies have
demonstrated that gamma-aminobutyric acidergic (GABAergic)
interneurons expressing the calcium-buffering protein parvalbu-
min (PV) drive gamma rhythms and promote cortical circuit
performance and cognitive ﬂexibility (9,10). Importantly, a recent
study has demonstrated that optogenetic stimulation of pyr-
amidal neurons in the medial prefrontal cortex in mice induces
social deﬁcits associated with enhanced gamma oscillations,
whereas coactivation of PV and pyramidal neurons does not
induce social deﬁcits (11). These results collectively suggest
that an increased neocortical E/I ratio caused by malfunctions of
PV-expressing interneurons induces excessive gamma oscilla-
tions and autistic-like behaviors.
FACTORS CONTRIBUTING TO E/I IMBALANCE
Neuronal E/I balance involves regulation at synaptic or circuit
levels. Speciﬁc factors that contribute to synaptic E/I balance
would include excitatory/inhibitory synapse development,
synaptic transmission and plasticity, downstream signaling
pathways, homeostatic synaptic plasticity, and intrinsic neuro-
nal excitability (Table 1). At the circuit level, E/I balance
involves local circuits such as the interplay between GABAer-
gic interneurons and target pyramidal neurons, which would
modulate long-range connections.
EXCITATORY SYNAPSE DEVELOPMENT
Cell adhesion molecules organize synapse development
through transsynaptic adhesion and synaptic protein recruit-
ment. Neuroligins and neurexins are prototypical members (6),f Biological Psychiatry. This is an open access article under the
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 1
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Table 1. Mechanisms Underlying E/I Imbalances in Animal Models of ASD
E/I Imbalance Mechanisms Examples of Animal Models of ASD
Excitatory Synapse Development Eif4ebp2 (12)
AMPARs BTBR (14), Emx1-Cre;Syngap11/ﬂ (35), Emx1-Cre;Syngap11/lox-stop (35), Mecp2 (28,29), Mecp2Tg1 (31), Shank3
duplication (27), Shank3 (various exon deletions) (19–24), Tau-Mecp2 (30), Syngap11/– (34), Ube3a (15)
NMDARs Baiap2 (IRSp53) (53), BALB/c (46,47), BTBR (45), Grid1 (GluD1) (44), Grin1 (GluN1) (37), Nlgn1 (38), Rats with low
prosocial USVs (48), Shank2 (exons 6–7) (39,40), Shank2 (exon 7) (41), Shank3 (exons 4–9) (18), Shank3 (exon 21G)
(23), Shank31/ΔC (43), Tbr11/– (40,42), VPA rats and mice (49–52)
mGluRs Baiap2 (IRSp53) (53), BTBR (61–63), Fmr1 (57–60,64,65), Nlgn3 (88), Shank2 (exons 6–7) (39)
Signaling Pathways BTBR (82), Cntnap2 (79), Emx1-Cre;Tsc1 (71), Fmr1 (76,78,81), Nf11/– (77), Nse-Cre;Pten (69), Pcp2/L7-Cre;Tsc1 (70),
Tsc21/– (72–74), Ube3a (15,75), Shank31/ΔC (43)
Inhibitory Synapse Development
and Function
D1-Cre;Nlgn3 (89), Fmr1 (92–94,96–98), Gabrb3 (90,91), Nlgn2 (84,85), Nlgn3 (86,87,89), Nlgn3 R451C (86,87,89), Ube3a
(101,102)
Interneurons BTBR (95,106,119), Cntnap2 (79,113), Cntnap4 (80), Dlx1/2;Scn1a1/ﬂ (118), Dlx5/6-Cre;Tsc1 (110), Fmr1 (108), Gad2
(GAD65) (106), Mecp2 (106,120), Nkx2.1-Cre;Pten (109), Nlgn3 R451C (2), Oxtr (127), Pvalb (112), PV-Cre;ErbB4 (123),
Pv-Cre;Mecp2 (107), PV-RFP;Shank1 (111), Scn1a1/– (118), Scn1a1/R1407X (117), Shank3 (exons 13–16) (106), SST-
Cre;Mecp2 (107), SynI (121,122), Ube3a (126), Viaat-Cre;Mecp2 (120), VPA mice (2)
Glial Cells Gfap-Cre;ERT2;Mecp2lox-stop/y (130), Gfap-Cre;Pten (129), Glast-CreERT2;Glt1 (128), Lysm-Cre;Mecp2lox-stop/y (131)
Intrinsic Neuronal Excitability Nestin-Cre;Foxp1 (133), Fmr1 (134), Pv-Cre;ErbB4 (124,125), Shank3 (exons 13–16) (135)
Homeostatic Synaptic Plasticity Fmr1 (140,141), Mecp2 (137–139)
Temporal E/I Regulation CreERT2;MECP2 and TG;Mecp2lox/y (148), CreERT2;Syngap11/lox-stop (146), CreEsr1*;Mecp2lox-stop/y (147), CreEsr1*;
Ube3aStop/p (149), Fmr1 (144,145), Nlgn3stop-tetO;Pcp2tTA (88), VPA rats (144,145)
Candidate mechanisms involved in causing E/I imbalances in some animal models of ASD. In some cases, more than one mechanism appears
to apply to the same mouse model, possibly due to multiple effects of a single mutation or homeostatic interplay among different mechanisms.
Additional studies may be needed to determine whether certain mechanisms listed here represent primary changes and, hence, fundamental
pathogenic mechanisms. Heterozygosity and conditional gene deletion or re-expression are indicated; all other gene names without additional
identiﬁers represent homozygosity (–/– or ﬂ/ﬂ) or X chromosomal/maternal deletion (Mecp2–/y;Ube3am–/p1). Full names of the genes and their known
functions are as follows: Baiap2 (brain-speciﬁc angiogenesis inhibitor 1-associated protein 2; also known as IRSp53; excitatory postsynaptic
adaptor and scaffolding protein); Cntnap2/4 (contactin-associated protein-like 2/4; a member of the neurexin family of cell protein 2); Eif4ebp2 (a
member of the eukaryotic translation initiation factor 4E binding protein family; bind eIF4E and inhibit translation initiation); ErbB4 (erb-b2 receptor
tyrosine kinase 4; a receptor for neuregulins with tyrosine kinase activity); Fmr1 (fragile X mental retardation 1; an RNA-binding protein that
regulates messenger RNA trafﬁcking); Foxp1 (forkhead box P1; a transcription factor); Gabrb3 (gamma-aminobutyric acid A receptor subunit beta 3;
a GABA receptor subunit); Gad2 (glutamic acid decarboxylase 2; also known as GAD65; a GABA-synthesizing enzyme); Glt1 (solute carrier family 1
[glial high afﬁnity glutamate transporter], member 2; also known as Sla1a2 or EAAT2, a glutamate transporter); Grid1 (glutamate receptor,
ionotropic, delta 1; also known as GluD1; a subunit of glutamate receptors); Grin1 (glutamate ionotropic receptor NMDA type subunit 1; also known
as GluN1; an NMDA receptor subunit); Mecp2 (methyl CpG binding protein 2; a transcription factor that binds to methylated DNA); Nf1
(neuroﬁbromin 1; a negative regulator of ras signaling); Nlgn1/2/3 (neuroligin 1/2/3; a synaptic cell adhesion molecule); Oxtr (oxytocin receptor); Pten
(phosphatase and tensin homolog; a phosphatase for phosphoinositides); Pvalb (parvalbumin; a calcium ion-binding protein); Scn1a (sodium
voltage-gated channel alpha subunit 1; a subunit of voltage-dependent sodium channels); Shank1/2/3 (excitatory postsynaptic scaffolding
proteins); Syngap1 (synaptic Ras GTPase activating protein 1, excitatory postsynaptic scaffolding protein with GTPase-activating protein activity);
SynI (synapsin I; a protein that associates with synaptic vesicles); Tbr1 (T-box, brain 1; a transcription factor); Tsc1/2 (tuberous sclerosis 1; a growth
inhibitory protein); Ube3a (ubiquitin protein ligase E3A; an E3 ubiquitin-protein ligase).
AMPAR, alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor; E/I, excitation/inhibition; GABA, gamma-aminobutyric acid;
GTPase, guanosine triphosphatase; mGluR, metabotropic glutamate receptor; NMDAR, N-methyl-D-aspartate receptor; USV, ultrasonic
vocalization; VPA, valproic acid.
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Given their critical roles in synapse and circuit development, it
is no wonder that neuroligin and neurexin genes have been
among the ﬁrst ASD-related genes identiﬁed in early autism
studies (6). Contrary to initial expectations, however, neuro-
ligin/neurexin knockout in mice did not induce signiﬁcant
changes in synapse number, except in a few speciﬁc brain
regions; instead, it substantially modiﬁed synaptic functions
(6), which may also contribute to impaired synaptic develop-
ment in ASDs.
A recent study has shown that neuroligin expression can be
altered indirectly. Knockout of 4E-BP2, known to inhibit eIF4E in
the mechanistic target of rapamycin (mTOR) pathway in mice
(Eif4ebp2, a member of the eukaryotic translation initiation
factor 4E binding protein family), upregulates neuroligins (all
four known isoforms), increases hippocampal synaptic E/I
ratio, and induces autistic-like behaviors (12). Pharmacologic
inhibition of eIF4E, or knockdown of neuroligin-1 (Nlgn1) but not2 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journalneuroligin-2 (Nlgn2), which are excitatory and inhibitory synapse
speciﬁc, respectively (6), normalizes the E/I ratio and rescues
autistic-like behaviors.AMPA RECEPTORS
Glutamatergic dysfunction involving alpha-amino-3-hydroxy-
5-methyl-4-isoxazole propionic acid (AMPA), N-methyl-D-
aspartate (NMDA), and metabotropic glutamate (mGluR)
receptors (AMPARs, NMDARs, and mGluRs) alters E/I bal-
ance. Supporting the role of AMPARs, social deﬁcits in BTBR
mice, an inbred mouse strain modeling ASD (13), are rescued
by the AMPAR-activator ampakine (14). Ampakine also res-
cues impaired long-term potentiation (LTP) and long-term
memory in Ube3a-deﬁcient mice (Ube3am–/p1) that lack the
maternal copy of an E3 ubiquitin ligase gene (15), a model of
Angelman syndrome, characterized by intellectual disability,
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smiling (16).
Mice heterozygous for Shank3 (exons 4–9 deletion), an
excitatory postsynaptic scaffold (17), show reduced evoked
AMPAR-mediated excitatory synaptic transmission, sup-
pressed LTP, and impaired motor function (18). These pheno-
types are rescued by insulin-like growth factor 1 (IGF-1) (19),
known to activate AMPARs, but not NMDARs, through the
PI3K pathway (20). Similar reductions in evoked AMPAR
transmission are observed in other Shank3-mutant mice
carrying different exon deletions (21–24), although two studies
on Shank3 mice report normal AMPAR transmission (25,26).
Conversely, an increase in spontaneous AMPAR transmission
is observed in mice carrying a Shank3 duplication, and seizure
and mania-like behaviors in these mice are corrected by the
mood-stabilizing agent valproic acid (VPA) (27).
Mice lacking the transcription regulator MeCP2, modeling
Rett syndrome, which is characterized by loss of language
and motor skills, show reduced spontaneous and evoked
AMPAR transmission and excitatory synaptic connectivity
(28,29). Conversely, mice with neuron-speciﬁc Mecp2 over-
expression show increased spontaneous AMPAR transmis-
sion (30) that is in line with dose-dependent changes in
spontaneous and evoked AMPAR transmission in autaptic
hippocampal neurons from transgenic mice (31). Similar to
Shank3 mice, IGF-1 treatment of Mecp2 mice partially rescues
the reduced spontaneous excitatory transmission, spine
density, and PSD-95 levels (an excitatory postsynaptic
scaffold) (32).
Syngap1 is an excitatory postsynaptic guanosine
triphosphatase-activating protein (Ras-GAP) implicated in
intellectual disability and ASD (33). Syngap1 heterozygous
mice show increased AMPAR transmission, precocious spine
development, and hyperactive circuits in the hippocampus,
and reduced seizure threshold at postnatal day 14 (P14) but
not at P7, P21, or P42 (34). Syngap1 haploinsufﬁciency
restricted to forebrain glutamatergic neurons (Emx1-Cre),
but not GABAergic neurons (glutamic acid decarboxylase 2
[Gad2-Cre]), induces similar phenotypes (35). In addition,
Syngap1 re-expression in forebrain glutamatergic neurons
(Emx1-Cre;Syngap11/lox-stop), but not in GABAergic neurons
(Gad2-Cre;Syngap11/lox-stop), rescues cognitive and emotional
deﬁcits (35). Therefore, an early, excessive excitatory trans-
mission in glutamatergic neurons impairs brain functions in
Syngap1 mice.NMDARs
Animal models of ASDs exhibit NMDAR dysfunction and
behavioral abnormalities that respond to NMDAR-modulating
reagents (36). Directly supporting the importance of NMDARs,
mice with 85% downregulation of the glutamate ionotropic 1
(GluN1) subunit of NMDARs (Grin1) show social deﬁcits and
repetitive behavior (37).
Nlgn1-mutant mice display NMDAR hypofunction and
increased grooming responsive to the NMDAR agonist
D-cycloserine (38). In addition, Shank2 mice (exons 6–7) show
NMDAR hypofunction and social deﬁcits rescued by
D-cycloserine (39), or clioquinol, a zinc chelator that enhances
NMDAR function through transsynaptic zinc delivery (40).Notably, other Shank2-mutant mice (exon 7) show enhanced
NMDAR function (41), suggesting that different mutations
in the same gene may cause NMDAR dysfunction in
opposite directions. Mice heterozygous for Tbr1, encoding
a transcription factor with targets that include the
GluN2B subunit of NMDARs, show NMDAR hypofunction
and social deﬁcits responsive to D-cycloserine (42) and
clioquinol (40).
Other Shank3 mice (Shank31/ΔC(exon21)) show NMDAR
hypofunction and social deﬁcits responsive to inhibition of
coﬁlin (43), a negative actin regulator. In addition, two different
Shank3 mouse lines (exons 4–9 and e21G) show similar
NMDAR hypofunction (23,24,26), although rescue attempts
were not made. Several other animal models, including
Grid1, BTBR, and BALB/c mice, and rats with low play-
related prosocial ultrasonic vocalizations, show autistic-like
behaviors that are rescued by D-cycloserine or other NMDAR
agonists (44–48), although NMDAR function remains to be
investigated.
At the other end of the spectrum, excessive NMDAR
function also appears to cause autistic-like behaviors. Rats
prenatally exposed to VPA show increased NMDAR levels,
enhanced NMDAR-dependent LTP, and hyperconnected local
neocortical circuits (49,50). The autistic-like behaviors in VPA
rodents are rescued by memantine (51,52). In addition,
mice lacking IRSp53, or Baiap2, an abundant excitatory
postsynaptic scaffold, show NMDAR hyperfunction and
social and cognitive impairments responsive to memantine
(53). These results collectively suggest that deviation of
NMDAR function in either direction leads to autistic-like
behaviors (36).mGluRs
Metabotropic glutamate receptors have long been implicated
in ASDs (54). A well-known example is mGluR5 hyperfunction
in mice lacking FMRP (Fmr1y/–), an RNA-binding protein
implicated in fragile X syndrome (55,56). These mice show
behavioral abnormalities that are rescued by mGluR5 antag-
onists (57–60). In addition, in BTBR mice, mGluR5 inhibition
rescues social deﬁcits and repetitive behaviors (61,62), as well
as hippocampus-dependent memory (63).
The causal role of mGluR5 hyperfunction is further sup-
ported by genetic rescue of mGluR5 signaling. Suppressing
exaggerated mGluR5 signaling in Fmr1 mice by crossing
them with mGluR5 heterozygous mice (Grm51/–) rescues
disease-related synaptic, biochemical, and behavioral pheno-
types (64). More recently, a genetic cross of Fmr1 mice
with Tsc2 heterozygous mice (Tsc21/–), which display
reduced mGluR5 signaling, rescued all disease-related
phenotypes (65).
Results obtained in studies related to glutamate receptor
malfunctions should be interpreted with care because the
three glutamate receptors can inﬂuence each other. For
instance, it is well known that AMPARs are regulated by
NMDARs and mGluRs. In addition, NMDARs and mGluRs can
exert synergistic actions (66,67); social deﬁcits in Shank2 mice
(exons 6–7), displaying NMDAR hypofunction, are rescued by
indirectly stimulating NMDARs using the mGluR5 agonist
CDPPB (39).Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journal 3
E/I Imbalance in Animal Models of ASD
Biological
PsychiatrySIGNALING PATHWAYS
Signaling pathways downstream or upstream of synaptic
receptors and channels can regulate E/I balance. The mTOR
pathway, known to be activated by NMDARs, mGluRs, and
receptor tyrosine kinases, has been implicated in fragile X
syndrome and ASDs (68). For instance, the mTOR inhibitor
rapamycin rescues autistic-like phenotypes in animal models
with heightened mTOR signaling, including Nse-Cre;Pten (69),
Tsc1 (Pcp2/L7-Cre;Tsc1, Emx1-Cre;Tsc1) (70,71), Tsc2
(Tsc21/–) (72–74), and Ube3a (75). In some studies, the most
downstream proteins in the mTOR pathway are targeted for
rescue; examples include eIF4E in Eif4ebp2-deﬁcient mice
(12), and S6K1 in Fmr1 mice (76).
Actin-modulatory pathways, important for actin-rich excita-
tory synapses, have also been implicated. Ampakine, which
rescues LTP and memory phenotypes in Ube3a mice, stabil-
izes synaptic actin ﬁlaments during LTP (15). In addition,
pharmacologic or genetic modulation of the actin-regulatory
proteins PAK and coﬁlin rescues autistic-like behaviors in
Nf1 (neuroﬁbromatosis type 1; Nf11/–) (77), Shank3 (Shank31/ΔC)
(43), and Fmr1 (78) mice.
Dopamine receptor agonists/antagonists and 5-hydro-
xytryptamine rescue autistic-like behaviors in Cntnap2 (encod-
ing contactin-associated protein-like 2) (79), Cntnap4 (80),
Fmr1 (81), and BTBR (82) mice, implicating monoaminergic
pathways. Although rescue mechanisms in these cases are
generally unclear, the Ras-PI3K-Akt pathway and GluA1-
dependent synaptic plasticity have been suggested for Fmr1
mice (81).INHIBITORY SYNAPSE DEVELOPMENT AND
FUNCTION
GABAergic signaling is frequently altered in animal models of
ASD (3,4,6), in line with many related human genetic variations
(5,6,83). Inhibitory synaptic adhesion molecules are important
regulators of GABAergic signaling. Virus-mediated deletion of
inhibitory synapse-speciﬁc Nlgn2 in the medial prefrontal
cortex leads to delayed (6–7 postnatal weeks) decreases in
inhibitory synapse density, miniature inhibitory postsynaptic
current (IPSC) frequency and amplitude, and evoked IPSC
input-output curves, effects that are accompanied by social
and cognitive deﬁcits (84). An earlier study also showed that
Nlgn2 deletion in mice suppresses GABAergic and glycinergic
transmission through impaired assembly of postsynaptic
receptor complexes at perisomatic inhibitory synapses (85).
Mice lacking Nlgn3, which is present at both excitatory and
inhibitory synapses and implicated in ASDs (6), show minimal
alterations in excitatory or inhibitory synapse density or func-
tion (86). However, recent studies have reported enhanced
GABAergic transmission at cholecystokinin-positive basket
cell synapses in the hippocampus (87) and impaired cerebellar
mGluR-dependent synaptic long-term depression (88).
Intriguingly, Nlgn3 knockin mice carrying a human mutation
(Nlgn3 R451C) show enhanced GABAergic transmission in the
somatosensory cortex, together with increased frequency of
spontaneous IPSCs and increased levels of the inhibitory
synaptic proteins vesicular GABA transporter (VGAT) and
gephyrin (86). In addition, the R451C knockin impairs4 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journalGABAergic transmission in PV basket cell synapses, but
enhances GABAergic transmission in cholecystokinin basket
cell synapses in the hippocampus (87), suggesting that the
same mutation induces distinct changes in GABAergic trans-
mission in different brain regions and cell types.
In the striatum, Nlgn3 deletion restricted to D1 medium spiny
neurons (D1-MSNs), but not D2-MSNs, suppresses GABAergic
transmission onto D1-MSNs (89). Importantly, re-expression of
Nlgn3, or K1 channel expression causing neuronal relaxation, in
Nlgn3-deﬁcient D1-MSNs rescues GABAergic transmission and
rotarod performance (89), suggesting that abnormally excited
D1-MSNs cause autistic-like phenotypes.
Altered GABA type A (GABAA) receptor levels or function
would directly affect E/I balance. A deﬁciency of the ASD-
associated β3 subunit of the GABAA receptor (Gabrb3) in
mice reduces GABAA receptor levels, enhances seizure
susceptibility, and induces cognitive and motor deﬁcits
(90,91). Reduced levels of GABAA receptor subunits are also
observed in Fmr1 mice (92–94). Moreover, the GABAA
receptor antagonist DMCM given to wild-type mice impairs
social interaction (95).
Tonic GABAergic transmission, involving extrasyn-
aptic GABAA receptors, appears to be altered in ASD model
animals. Fmr1 mice show reduced tonic but not phasic
GABA currents in the subiculum (96), reduced phasic and
tonic GABA currents in the amygdala (97), and increased
phasic GABA currents due to enhanced GABA release in the
striatum (tonic currents were not measured) (98), indicative of
heterogeneous effects of Fmr1 deletion. Importantly, the
GABA agonist 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol
(THIP), a selective enhancer of tonic GABA currents, rescues
hyperexcitability of principal neurons in the Fmr1-deﬁcient
amygdala (97). Therefore, deceased GABAergic signaling, in
addition to enhanced mGluR signaling, may contribute to
fragile X syndrome (3,99,100).
Decreased tonic inhibition is also observed in cerebellar
granule cells of Ube3a mice, which have increased levels of
GABA transporter 1, a substrate of UBE3A, and reduced levels
of ambient GABA (101). These changes accompany abnormal
Purkinje cell ﬁring and cerebellar ataxia, both of which are
rescued by THIP (101). In the hippocampus, however, UBE3A
deﬁciency enhances neuregulin-ErbB4 (Erb-B2 receptor tyro-
sine kinase 4) signaling and GABAergic output, and the
resulting impairments in LTP in target pyramidal neurons and
contextual fear memory are rescued by the ErbB inhibitor
PD158780 (102), or the GABAA antagonist bicuculline (LTP
rescue) (102). These results suggest that UBE3A deletion can
cause region-speciﬁc changes in GABAergic signaling, which
can interact with excitatory synaptic function.INTERNEURONS
GABAergic interneurons are associated with various neuro-
logical and psychiatric disorders (3,4,103). Many ASD-
associated genes are expressed in interneurons, and their
mutations impair interneuronal development and input/output
function, including dendritic synapse development and func-
tion, neuronal excitability and ﬁring, nerve terminal develop-
ment and function (i.e., GABA synthesis, packaging, and
release), and inhibitory synapse formation with target neurons.
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PV interneurons are critical regulators of gamma oscilla-
tions and are associated with various psychiatric disorders
(9,10,104). Their functional importance is supported by the
impaired multisensory integration (MSI) in the insular cortex,
known to exhibit reduced connectivity in ASDs (105), observed
in BTBR, Gad2(GAD65), Mecp2, and Shank3 mice (106).
Intriguingly, diazepam-treated adult BTBR mice show normal-
ized MSI, whereas diazepam-treated control mice show
impaired MSI (106), indicative of an optimum range of PV
neuron inhibition. In addition, diazepam-treated young BTBR
mice show normal MSI at adult stages (106), suggesting that
early treatment has long-lasting effects. GABAergic interneur-
ons other than PV such as somatostatin (SST), calretinin, and
neuropeptide Y (NPY) are also important for ASDs. For
instance, Mecp2 deletion restricted to PV and SST interneur-
ons leads to distinct phenotypes; motor, sensory, memory,
and social deﬁcits in PV-Mecp2 knockout; and seizures and
stereotypies in SST-Mecp2 knockout (107).
One of the speciﬁc interneuronal defects observed in animal
models is reduced cell density. PV interneuron density is
decreased in mouse models, including Fmr1 (108), VPA (2),
Nlgn3 R451C (2), and Cntnap2 (79). Non-PV interneuronal
density is also altered. Cntnap2 mice show reduced calretinin
and NPY interneuron counts, in addition to PV interneuronal
reduction (79). Pten knockout restricted to cortical GABAergic
interneuronal progenitors (Nkx2.1-Cre;Pten) preferentially
decreases SST cell counts (relative to PV), leading to increases
in PV-SST cell ratio and target-neuron inhibition (109). In
addition, Tsc1 knockout in GABAergic interneuronal progen-
itors (Dlx5/6-Cre;Tsc1) decreases calretinin and NPY cell
counts and seizure threshold (110).
Interneuronal input/output function can also be compro-
mised. Deﬁciency of Shank1, highly expressed in PV cells,
suppresses excitatory synaptic input and GABAergic output of
PV interneurons, increasing E/I ratio in target neurons (111).
Mice lacking PV (Pvalb) show altered short-term plasticity of
excitatory cortical inputs to PV interneurons and social deﬁcits
and repetitive behavior (112). Cntnap2 mice show suppressed
perisomatic evoked IPSC input-output curve (113), in addition
to reduced PV cell counts, defective neuronal migration, and
epilepsy (79). However, CNTNAP2 also regulates dendrite and
spine development and AMPAR trafﬁcking in pyramidal neu-
rons (114–116), suggesting that it regulates both excitatory
and inhibitory synapses.
Impaired interneuronal ﬁring would suppress GABAergic
signaling. Mice heterozygous for the voltage-gated sodium
channel Nav1.1 (Scn1a1/-), a model for Dravet syndrome
characterized by intractable seizure and social and cognitive
deﬁcits, show limited action potential ﬁring and GABAergic
output, together with social and spatial and fear memory
deﬁcits (117,118). These features are recapitulated by
Nav1.1 knockout restricted to forebrain GABAergic interneur-
ons (Dlx1/2-Cre;Scn1a1/–) and are rescued by the GABAA
receptor agonist clonazepam (118). Similarly, BTBR mice
show reduced hippocampal spontaneous IPSC frequency
and social and cognitive deﬁcits responsive to clonazepam
(95), similar to the improved social avoidance observed in
diazepam-treated BTBR mice (119).Limited nerve terminal development and function would
affect GABAergic signaling. Mice lacking Mecp2 in GABAergic
interneurons (Viaat-Cre;Mecp2) show reduced quantal GABA
content and messenger RNA levels for GABA-synthesizing
GAD65 and GAD67 (120). Mice lacking the synaptic vesicle
protein synapsin I (SynI), implicated in ASD and epilepsy, show
epileptic propensity, and neurons from these mice re-
expressing a disease-related mutant SynI display reduced
readily releasable pool of GABA-containing vesicles and
stronger short-term depression (121), which may involve
abnormally activated eEF2K/eEF2 signaling (122). Conditional
deletion of ErbB4 in PV neurons causes reduced neuregulin-
dependent GABA release in the prefrontal cortex and cognitive
deﬁcits that are rescued by diazepam (123), results in line with
the increased seizure susceptibility observed in these mice
(124,125). Ube3a mice show reduced GABAergic output in the
visual cortex due to reduced defective presynaptic vesicle
cycling prominent at P80 but not at P25 (126).
Dysfunctional interneurons would fail to properly develop
inhibitory synapses with target neurons. A deﬁciency of
CNTNAP4, highly expressed in developing interneurons, in
mice causes reduced PV interneuronal output through limited
inhibitory synapse maturation, as evidenced by widened
synaptic cleft gap, and enhanced startle responses rescued
by the GABAA receptor agonist Indiplon (80). In addition, mice
lacking the oxytocin receptor (Oxtr) show decreased hippo-
campal inhibitory presynaptic density and increased seizure
susceptibility, together with social and learning defects
responsive to prosocial neuropeptides, oxytocin and vaso-
pressin (127), although rescue mechanisms downstream of
receptor activation remain unclear.GLIAL CELLS
Glial cell dysfunctions can disturb neuronal E/I balance.
Supporting astrocytic contribution, astrocyte-speciﬁc deletion
of GLT1 (Glast-CreERT2;Glt1), a glutamate transporter
expressed in neurons and glia, induces increased excitatory
transmission, seizure susceptibility, and repetitive behavior
that is responsive to memantine (128). Mice lacking PTEN in
astrocytes (Gfap-Cre;Pten) show abnormal excitatory syn-
apse structure and reduced excitatory transmission and LTP
(129). In addition, astrocyte-speciﬁc re-expression of Mecp2
in Mecp2-deﬁcient mice restores disease-related phenotypes,
including premature lethality, abnormal respiration, hypoactiv-
ity, and reduced dendritic complexity [a noncell-autonomous
effect (130)]. Nonastrocytic glial cells such as microglia and
oligodendrocytes are also important. For instance, microglia-
speciﬁc re-expression of MeCP2 in Mecp2 mice (Lysm-Cre;
Mecp2lox-stop/y) ameliorates disease-related phenotypes (131).INTRINSIC NEURONAL EXCITABILITY
Neuronal excitability acts together with synaptic E/I balance to
modulate neuronal ﬁring. Rats prenatally exposed to VPA
show reduced neuronal excitability in addition to enhanced
NMDAR function and NMDAR-dependent LTP (50,132).
Interestingly, both enhanced NMDAR function and reduced
excitability peak around birth and are progressively and
concurrently corrected to normal levels within 3 weeks (132),Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journal 5
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function. Similarly, enhanced excitatory transmission and
reduced excitability are observed in brain-speciﬁc Foxp1-
deﬁcient mice (Nestin-Cre;Foxp1), which display social impair-
ments and repetitive behavior (133).
An important regulator of intrinsic excitability is dendritic ion
channels. Fmr1 mice show reduced expression and impaired
function of dendritic h- and BKCa (big potassium) channels in
cortical pyramidal neurons, associated with dendritic hyper-
excitability and sensory hypersensitivity that are corrected by
the BKCa channel activator, BMS-191011 (134). Recently,
reduced h-channel function has been reported in Shank3-
deﬁcient mouse and human neurons (135).
Some intrinsic excitability mechanisms seem to overlap with
ASD mechanisms. Neuregulin-ErbB4 signaling, an aforemen-
tioned regulator of interneuronal GABAergic output, increases
the intrinsic excitability of PV interneurons by inhibiting the
voltage-dependent potassium channel, KV1.1 (124,125).HOMEOSTATIC SYNAPTIC PLASTICITY
Homeostatic plasticity works at the level of neuronal synapses
in addition to intrinsic neuronal excitability (136). Mecp2 mice
show impaired upward excitatory synaptic scaling in visual
cortical neurons (137) and downward scaling in hippocampal
neurons (138,139). Fmr1 mice show blocked upward excita-
tory synaptic scaling in the hippocampus (140), and upward
inhibitory synaptic scaling in the amygdala (141). In addition,
GKAP/DLGAP1/SAPAP1, a postsynaptic scaffold implicated in
ASD, regulates hippocampal excitatory synaptic scaling in a
bidirectional manner (142).TEMPORAL E/I REGULATION
Synaptic and circuit E/I balances are established and ﬁne-
tuned during brain development and through sensory experi-
ence. In immature brains, GABA acts as an excitatory neuro-
transmitter because of the prevailing high intracellular chloride
concentration ([Cl–]i) (143). The high [Cl
–]i built up by the
chloride importer, NKCC1, is gradually diminished by the
chloride exporter KCC2, shifting GABA action from depolari-
zation to hyperpolarization. The depolarizing GABA action is
transiently inhibited during birth by maternal oxytocin, but is
abnormally suppressed in Fmr1 mice and VPA rats (144).
Elegantly, maternal pretreatment with the NKCC1 blocker
bumetanide before delivery normalizes disease phenotypes
in both models (P15) (144). In addition, bumetanide rescues
impaired ultrasonic vocalization in pups (P4) (144) and social
deﬁcits in adult offspring (2.5/4.5 months) (145), suggesting
that an early E/I imbalance has long-lasting effects (143).
Another example of temporal E/I imbalance is Syngap1
heterozygous mice. In these mice, induction of a Syngap1
mutation in adult mice (.8 weeks) does not alter synaptic
function, but restoration of Syngap1 expression in newborn
Syngap1-mutant mice at P1 improves cognitive and memory
functions (34,146), suggesting again that an early E/I imbal-
ance has long-lasting effects.
However, there are cases in which delayed restoration
rescues abnormal phenotypes. For instance, re-expression of
Nlgn-3 in Nlgn3-deﬁcient mice at P30 restores mGluR1α6 Biological Psychiatry ]]], 2016; ]:]]]–]]] www.sobp.org/journalexpression and ectopic synapse formation in the cerebellum
(88). In addition, re-expression of Mecp2 in adult Mecp2 mice
(12–17 weeks) restores LTP and disease-related pheno-
types (147), and, conversely, genetic or antisense-mediated
Mecp2 suppression in adult Mecp2-overexpressing mice
(7–8 to 11–12 weeks) rescues major phenotypes (148). More-
over, re-expression of maternal Ube3a in Ube3a mice at 3, 6,
and 12 weeks differentially rescue disease-related phenotypes
(149), collectively suggesting that ASD-related mutations have
distinct time course of phenotype development and reversibility.
PERSPECTIVES
To minimize the difﬁculty of differentiating primary and sec-
ondary changes in animal models of ASD, we have sought in
this review to highlight studies that attempted pharmacologic
rescue and conditional knockout/rescue experiments.
However, care should be taken in interpreting these results
because the observed rescues may merely represent apparent
phenotypic alleviation rather than fundamental correction of
key pathogenic mechanisms. In addition, the phenotypes
observed in conditional knockout mice, although clearer than
those from conventional knockouts, may not represent the
consequences of the intricate interplay among different cell
types that occurs in real pathological conditions.
Adding to this complexity, a substantial portion of the
primary pathological changes likely occurs during embryonic
or early postnatal periods and exerts long-lasting effects.
Therefore, the rescue results obtained using adult animals
may not necessarily provide insights into early and primary
changes. We thus need to identify key mechanisms that
contribute to the initiation, development, and maintenance of
autistic-like phenotypes along the temporal axis. These efforts
would need to involve genetic manipulations and pharmaco-
logic interventions at different time points, and observation of
their short- and long-term consequences.
Pathogenic mechanisms underlying E/I imbalance in ASDs
are more complex than might have been expected. Recent
studies have even begun to show that the same gene mutation
leads to distinct synaptic E/I imbalances in different synapses,
cell types, and brain regions at different time points. Collec-
tively, these ﬁndings highlight the importance of pursuing
detailed and integrative analyses of E/I imbalances in future
studies of animal models of ASD.ACKNOWLEDGMENTS AND DISCLOSURES
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